Stockreport

Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring P [Read more]